A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (P04938)

NCT01155466 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

778

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson Disease

Interventions

DRUG: Preladenant 2 mg tablet
DRUG: Preladenant 5 mg tablet
DRUG: Preladenant 10 mg tablet
DRUG: Placebo to Preladenant Tablet
DRUG: Rasagiline 1 mg capsule
DRUG: Placebo to Rasagiline capsule

Sponsor

Merck Sharp & Dohme LLC